New cell therapy JY231 targets tough leukemia in early human test
NCT ID NCT06514768
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study is testing a new treatment called JY231 for people with B-cell acute lymphoblastic leukemia (B-ALL), a type of blood cancer. The main goal is to check if JY231 is safe and tolerable, and to see if it can help control the disease. About 20 adults and children up to age 75 will take part. The treatment uses specially designed cells to target and attack cancer cells that have a marker called CD19.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
920th HJointLogistics
RECRUITINGKunming, Yunnan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can antibody infusions outperform antibiotics in shielding CAR-T patients from infections?
- Can targeted drugs blinatumomab and venetoclax improve outcomes for childhood leukemia?
- Leukemia treatment may erase vaccine protection—study tests if re-vaccination works
- New CAR T-Cell therapy shows promise for kids with tough leukemia
- Experimental cell therapy targets tough blood cancers and anemia
- New hope for tough leukemia: experimental drug AZD0486 enters human trials